Division of Oncology, S. Orsola-Malpighi Hospital, Via Albertoni n 15, 40138, Bologna, Italy.
Department of Pathology AOUI, University of Verona, Verona, Italy.
Mol Diagn Ther. 2019 Oct;23(5):569-577. doi: 10.1007/s40291-019-00414-0.
9p loss appears a reliable and promising marker able to differentiate specific categories of patients with renal cell carcinoma associated with a worse prognosis.
The aim was to systematically evaluate relative risk of death, cancer-specific survival (CSS) and disease-free survival (DFS) among patients harboring 9p loss.
We found a total of 92 potentially relevant articles focused on the detection of 9p loss in patients with renal cell carcinoma and clinical outcomes of this population. Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines were employed to carry out this work. Fourteen studies resulted to be eligible for this analysis; 11 of these reported data on 5-year overall survival, six on CSS and four on DFS. An increased risk of death has been observed in patients harboring 9p loss (pooled relative risk of 3.965; 95% confidence interval [CI] 2.647-5.940, p < 0.001). Similarly, worse CSS (hazard ratio [HR] 6.776; 95% CI 3.824-12.009; p < 0.001) and DFS (HR 2.914; 95% CI 1.245-6.819; p = 0.014) have been observed in this population. Heterogeneity was significant in survival analysis, while no significant heterogeneity was observed in the CSS and DFS analyses.
Patients harboring chromosome 9p loss have worse clinical outcomes in terms of overall survival, CSS and DFS.
9p 缺失似乎是一种可靠且有前途的标志物，能够区分与预后较差相关的特定类别的肾细胞癌患者。
旨在系统评估携带 9p 缺失的患者的死亡相对风险、癌症特异性生存（CSS）和无病生存（DFS）。
我们共发现了 92 篇可能与检测肾细胞癌患者 9p 缺失及其人群临床结局相关的潜在相关文章。采用系统评价和荟萃分析首选报告项目（PRISMA）指南开展此项工作。有 14 项研究符合纳入分析的标准；其中 11 项报告了 5 年总生存率数据，6 项报告了 CSS 数据，4 项报告了 DFS 数据。携带 9p 缺失的患者死亡风险增加（合并相对风险 3.965；95%置信区间[CI]2.647-5.940，p<0.001）。同样，该人群的 CSS（风险比[HR]6.776；95%CI3.824-12.009；p<0.001）和 DFS（HR2.914；95%CI1.245-6.819；p=0.014）也较差。在生存分析中存在显著的异质性，而在 CSS 和 DFS 分析中则未观察到显著的异质性。
携带染色体 9p 缺失的患者在总生存率、CSS 和 DFS 方面具有更差的临床结局。
